A breakthrough in lung cancer - the biggest prize in immunotherapy

A breakthrough in lung cancer - the biggest prize in immunotherapyAndrew McConaghie

AstraZeneca/MedImmune hopes its immunotherapy combinations will help it catch up with leaders.The exciting new generation of immuno-oncology drugs, led by Merck's Keytruda and Bristol-Myers Squibb's (BMS) Opdivo have arrived, and... Read more

Two critical factors to attain marketing excellence

Two critical factors to attain marketing excellenceZoe Dunn

Companies need to commit to innovation and build meaningful, long-term relationships with patients to bring longer-term benefits on top of the short-term gains.How do brands know when they have achieved... Read more

Political dynamite - England’s Cancer Drugs Fund

Political dynamite - England’s Cancer Drugs FundLeela Barham

Proposals to consider cost in decisions about what will, and, crucially, won't, be paid for by the Cancer Drugs Fund (CDF) in England are the latest changes in the controversial... Read more

Patient perspective: a fair price for life-extending drugs

Patient perspective: a fair price for life-extending drugsSally Greenbrook

Today, most deaths in breast cancer are caused by secondary breast cancer. However, the high costs of drugs to slow its progress and the limits of the Cancer Drugs Fund... Read more